Monday, 25 Sep 2017

You are here

The RheumNow Week in Review – 25 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on IL-1 and pregnancy, contraceptives and the risk of RA, Calprotectin the biomarker, T2T failing, and the loss of a giant in rheumatology.

  1. Data on IL-1 inhibitors and pregnancy: 11 paternal & 31 maternal (23 Anakinra, 8 Cannakinumab) exposures, mosly live births and only  1 renal agenesis/ectopic neurohypophysis.  https://buff.ly/2wstyyA
  2. 435 Nordic JIA pts, Uveitis found in 20.5%; 90% asympt. Predictors of uveitis were ANA+, AHA+, JIA onset <7yrs in girls, not boys  https://buff.ly/2ise342
  3. Study of 215 RA patients Rx with DMARDs & T2T strategy. Serum Calprotectin shown to be strong biomarker; significantly correlated with ESR, CDAI, US Power doppler, Xray progression https://t.co/82YvTFtcAV
  4. 4666 elderly Canadian RA patients, only 59% were deemed to be adherent to biologic therapy, Nonadherent used more steroids https://t.co/kmEmgmmc4p
  5. 55% Americans take prescription medicine; now more than ever. https://t.co/3ytMXHHhVP
  6. Swedish EIRA study: Oral contraceptive use decreases risk of ACPA+ RA. breast feeding has no effect. Ever/past oral contraceptive users have a decreased risk of ACPA-positive RA (OR=0.84) https://t.co/7p9wpfHBJY
  7. Ironwood announces FDA approval of its combo drug lesinurad/allopurinol (Duzallo) in a 200/300 tablet. Could this be useful? https://t.co/lcUZTieKqg
  8. 30 yoF with non itchy, nonpainful palpable purpura lesions on legs & abdomen on/off for last 8 mos. Patient has Hx of HBV Rx with Tenovir. What would you do next?
  9. Leukocytoclastic vasculitis is most commonly caused by antibiotic use (Cipro, Cefazolin ) https://t.co/I893XN737C
  10. Non-Tuberculous Mycobacterial Infections - Diagnosis and Management for the Rheumatologist
  11. IV Golimumab Shines in Psoriatic Arthritis  
  12. Treat-to-Target a Bust with Rheumatologists   
  13. It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk 
  14. Dr. H. Ralph Schumacher (1933-2017) 
  15. Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

22 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses survey results on membranous nephritis and patient perceptions of steroids, nonadherence, celebrity arthritis and IgG4 treatment.

CDC: 40% of U.S Adults Claim to Have Arthritis

The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Why Rheumatologists Should Do Better Vaccinating this Flu Season

It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al. showed that patients with rheumatoid arthritis are at increased risk for influenza regardless of DMARD/biologic use and may have a 2.75-fold increased incidence of related complications (https://buff.ly/2gYNTSz).

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk, and what Rheums think of ACR/EULAR criteria.